Skip to main content
. 2023 Oct 27;51(22):12092–12110. doi: 10.1093/nar/gkad936

Figure 2.

Figure 2.

PARP1 inhibition alters CTCF/Cohesin binding. (A) CTCF ChIP-qPCR in SNU719 cell line following PARP1 inhibition with 5uM Olaparib treatment for the main CTCF binding sites. (B) ChIP-qPCR in SNU719 cell line following PARP1 inhibition for SMC1 Cohesin subunit in all three replicates for the same CTCF binding sites. (C) CTCF ChIP-qPCR in YCCEL1 cell line following PARP1 inhibition with 5uM Olaparib treatment for the main CTCF binding sites. (D) ChIP-qPCR in YCCEL1 cell line following PARP1 inhibition for SMC1 Cohesin subunit in all three replicates for the same CTCF binding sites. Data are presented as %input. N = 3, Mean ± SD. The t test P values for the Olaparib/Ctrl comparison are indicated as asterisks (**** P ≤  0.0001, *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05).